Screener / SEC EDGAR /CIK 0000874716 /10-K filed Feb 20, 2026, compared with Feb 21, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Diagnostics

Idexx Laboratories IDXX

IDEXX was incorporated in Delaware in 1983. 10-K, Item 1

Headquarters
Westbrook, ME
CEO
Jonathan J. Mazelsky
Next results
around Feb 1, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $4.3B through the costs to a net profit of $1.1B · income statement of the 10-K

32% operating margin
Revenue to Gross profit: $2.7BRevenue to Cost of revenue: $1.6BGross profit to Operating profit: $1.4BGross profit to Operating expenses: $1.3BOperating profit to Net profit: $1.1BOperating profit to Tax & other: $300.6MOperating expenses to R&D: $251.2MOperating expenses to Sales, admin & other: $1.0B Revenue: $4.3B REVENUE $4.3B +10% Y/Y Gross profit: $2.7B · 62% margin GROSS PROFIT $2.7B 62% margin · +12% Y/Y Cost of revenue: $1.6B · 38% of revenue COST OF REVENUE $1.6B 38% of revenue Operating profit: $1.4B · 32% margin OPERATING PROFIT $1.4B 32% margin · +21% Y/Y Operating expenses: $1.3B · 30% of revenue OPERATING EXPENSES $1.3B 30% of revenue Net profit: $1.1B · 25% margin NET PROFIT $1.1B 25% margin · +19% Y/Y Tax & other: $300.6M · 7% of revenue TAX & OTHER $300.6M 7% of revenue R&D: $251.2M · 6% of revenue R&D $251.2M 6% of revenue Sales, admin & other: $1.0B · 24% of revenue SALES, ADMIN & OTHER $1.0B 24% of revenue
Gross profit $2.7B 62% margin · +12% Y/Y
Operating profit $1.4B 32% margin · +21% Y/Y
Net profit $1.1B 25% margin · +19% Y/Y
The full income statement, year by year

IDXX among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 59 peers the company is above, not a score.

Compare
Revenue growth: 10.4%, above 73% of 59 peers (their median 7.1%) REVENUE GROWTH 10.4% · above 73% Gross margin: 62.7%, above 46% of 50 peers (their median 65.2%) GROSS MARGIN 62.7% · above 46% Operating margin: 32.3%, above 94% of 50 peers (their median 13.4%) OPERATING MARGIN 32.3% · above 94% Net margin: 25.4%, above 88% of 59 peers (their median 9.5%) NET MARGIN 25.4% · above 88% FCF margin: 28.0%, above 93% of 55 peers (their median 15.2%) FCF MARGIN 28.0% · above 93% Return on capital: 48.5%, above 100% of 41 peers (their median 9.0%) RETURN ON CAPITAL 48.5% · above 100%
IDXX Peer median Below the median

What changed

2 new risk paragraphs. 10-K filed Feb 20, 2026 against Feb 21, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 11 checks found nothing to note

  • Receivables +16.6% vs revenue +10.4% (+6.2 pts)
  • Cash from operations $1.2B vs net income $1.1B (FY ending Dec 31, 2025)
  • Inventory -1.1% vs revenue +10.4% (-11.5 pts)
8 more checks with nothing to note
  • Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Revenue Recognition from Certain Product and Service Revenue
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

2 paragraphs in Risk Factors that were not in the 10-K filed Feb 21, 2025. Quoted as filed.

All 2 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 21, 2025 10-K, ITEM 1A
    We, and some of our third-party vendors, have experienced cybersecurity attacks by threat actors (which may include state-sponsored organizations or nation state actors) and other cybersecurity breaches and incidents in the past, including, among other things, computer viruses and malware, ransomware, denial of service actions, phishing…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$3.4B$3.7B$3.9B$4.3B
Net income$679.1M$845.0M$887.9M$1.1B
Operating cash flow$543.0M$906.5M$929.0M$1.2B
Free cash flow$394.1M$772.9M$808.1M$1.1B

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$4.3B ▲ 10.4% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

7 filings in the last 30 days · SEC EDGAR

All filings
2 more

About the company

Idexx Laboratories, Westbrook, ME · from the 10-K filed Feb 20, 2026

IDEXX was incorporated in Delaware in 1983. We develop, manufacture, and distribute products and provide services primarily for the companion animal veterinary; livestock, poultry and dairy; and water testing industries. We also manufacture and sell human medical point-of-care diagnostic products. Our primary products and services are: • Point-of-care veterinary diagnostic products, comprised of instruments, consumables, and rapid assay test kits;

Headquarters
Westbrook, ME
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 2, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Feb 20, 2026 (open at SEC), compared with the 10-K filed Feb 21, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/IDXX/export.csv") into a cell.